Supporting informed decision making for prostate specific antigen (PSA) testing on the web: an online randomized controlled trial

Rhodri Evans, Natalie Joseph-Williams, Adrian Edwards, Robert G Newcombe, Patricia Wright, Paul Kinnersley, Jeff Griffiths, Mari Jones, Janet Williams, Richard Grol, Glyn Elwyn, Rhodri Evans, Natalie Joseph-Williams, Adrian Edwards, Robert G Newcombe, Patricia Wright, Paul Kinnersley, Jeff Griffiths, Mari Jones, Janet Williams, Richard Grol, Glyn Elwyn

Abstract

Background: Men considering the prostate specific antigen (PSA) test for prostate cancer, an increasingly common male cancer, are encouraged to make informed decisions, as the test is limited in its accuracy and the natural history of the condition is poorly understood. The Web-based PSA decision aid, Prosdex, was developed as part of the UK Prostate Cancer Risk Management Programme in order to help men make such informed decisions.

Objectives: The aim of this study was to evaluate the effect of the Web-based PSA decision aid, Prosdex, on informed decision making.

Methods: A Web-based randomized controlled trial was conducted in South Wales, United Kingdom. Men aged 50 to 75 who had not previously had a PSA test were randomly allocated to two intervention and two control groups. Participants in the intervention groups either viewed Prosdex or were given a paper version of the text. The main outcome measures were the three components of informed decision making: (1) knowledge of prostate cancer and PSA, (2) attitude toward PSA testing, (3) behavior using a proxy measure, intention to undergo PSA testing. Decisional conflict and anxiety were also measured as was uptake of the PSA test. Outcomes were measured by means of an online questionnaire for the Prosdex group, the paper version group, and one of two control groups. Six months later, PSA test uptake was ascertained from general practitioners' records, and the online questionnaire was repeated. Results are reported in terms of the Mann-Whitney U-statistic divided by the product of the two sample sizes (U/mm), line of no effect 0.50.

Results: Participants were 514 men. Compared with the control group that completed the initial online questionnaire, men in the Prosdex group had increased knowledge about the PSA test and prostate cancer (U/mn 0.70; 95% CI 0.62 - 0.76); less favourable attitudes to PSA testing (U/mn 0.39, 95% CI 0.31 - 0.47); were less likely to undergo PSA testing (U/mn 0.40, 95% CI 0.32 - 0.48); and had less decisional conflict (U/mn 0.32, 95% CI 0.25 - 0.40); while anxiety level did not differ (U/mn 0.50, 95% CI 0.42 - 0.58). For these outcomes there were no significant differences between men in the Prosdex group and the paper version group. However, in the Prosdex group, increased knowledge was associated with a less favourable attitude toward testing (Spearman rank correlation [rho] = -0.49, P < .001) and lower intention to undergo testing (rho = -0.27, P = .02). After six months, PSA test uptake was lower in the Prosdex group than in the paper version and the questionnaire control group (P = .014). Test uptake was also lower in the control group that did not complete a questionnaire than in the control group that did, suggesting a possible Hawthorne effect of the questionnaire in favour of PSA testing.

Conclusions: Exposure to Prosdex was associated with improved knowledge about the PSA test and prostate cancer. Men who had a high level of knowledge had a less favourable attitude toward and were less likely to undergo PSA testing. Prosdex appears to promote informed decision making regarding the PSA test.

Trial registration: ISRCTN48473735; http://www.controlled-trials.com/ISRCTN48473735 (Archived by WebCite at http://www.webcitation.org/5r1TLQ5nK).

Conflict of interest statement

None declared

Figures

Figure 1
Figure 1
Prosdex RCT CONSORT participant flow chart

References

    1. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess. 1997;1(2):1–96.
    1. UK National Screening Committee, authors. Prostate Cancer Risk Management Programme. Sheffield, United Kingdom: National Health Service; 2001.
    1. Marteau T M, Dormandy E, Michie S. A measure of informed choice. Health Expect. 2001 Jun;4(2):99–108. doi: 10.1046/j.1369-6513.2001.00140.x.hex140
    1. Marteau T. Edwards A, Elwyn G, editors. Shared Decision Making in Health Care: Achieving Evidence-based Patient Choice. 2nd edition. Oxford, United Kingdom: Oxford University Press; 2009. Informed choice: a construct in search of a name; pp. 87–94.
    1. O'Connor AM, Bennett CL, Stacey D, Barry M, Col NF, Eden KB, Entwistle VA, Fiset V, Holmes-Rovner M, Khangura S, Llewellyn-Thomas H, Rovner D. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2003;2:CD001431. doi: 10.1002/14651858.
    1. Cardiff University. Prosdex .
    1. Elwyn Glyn, O'Connor Annette, Stacey Dawn, Volk Robert, Edwards Adrian, Coulter Angela, Thomson Richard, Barratt Alexandra, Barry Michael, Bernstein Steven, Butow Phyllis, Clarke Aileen, Entwistle Vikki, Feldman-Stewart Deb, Holmes-Rovner Margaret, Llewellyn-Thomas Hilary, Moumjid Nora, Mulley Al, Ruland Cornelia, Sepucha Karen, Sykes Alan, Whelan Tim International Patient Decision Aids Standards (IPDAS) Collaboration. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006 Aug 26;333(7565):417. doi: 10.1136/.
    1. Volk Robert J, Hawley Sarah T, Kneuper Suzanne, Holden E Wayne, Stroud Leonardo A, Cooper Crystale Purvis, Berkowitz Judy M, Scholl Lawrence E, Saraykar Smita S, Pavlik Valory N. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med. 2007 Nov;33(5):428–434. doi: 10.1016/j.amepre.2007.07.030.S0749-3797(07)00497-7
    1. Evans Rhodri, Edwards Adrian, Brett Joanne, Bradburn Mike, Watson Eila, Austoker Joan, Elwyn Glyn. Reduction in uptake of PSA tests following decision aids: systematic review of current aids and their evaluations. Patient Educ Couns. 2005 Jul;58(1):13–26. doi: 10.1016/j.pec.2004.06.009.S0738-3991(04)00199-5
    1. Frosch Dominick L, Bhatnagar Vibha, Tally Steven, Hamori Charles J, Kaplan Robert M. Internet patient decision support: a randomized controlled trial comparing alternative approaches for men considering prostate cancer screening. Arch Intern Med. 2008 Feb 25;168(4):363–9. doi: 10.1001/archinternmed.2007.111. 168/4/363
    1. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz K F, Simel D, Stroup D F. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA. 1996 Aug 28;276(8):637–9. doi: 10.1001/jama.276.8.637.
    1. Edwards A, Elwyn G, Hood K, Atwell C, Robling M, Houston H, Kinnersley P, Russell I Study Steering Group. Patient-based outcome results from a cluster randomized trial of shared decision making skill development and use of risk communication aids in general practice. Fam Pract. 2004 Aug;21(4):347–54. doi: 10.1093/fampra/cmh402. 21/4/347
    1. Evans Rhodri, Elwyn Glyn, Edwards Adrian, Newcombe Robert, Kinnersley Paul, Wright Pat, Griffiths Jeff, Austoker Joan, Grol Richard. A randomised controlled trial of the effects of a web-based PSA decision aid, Prosdex. Protocol. BMC Fam Pract. 2007;8(58):58. doi: 10.1186/1471-2296-8-58. 1471-2296-8-58
    1. Evans Rhodri, Elwyn Glyn, Edwards Adrian, Watson Eila, Austoker Joan, Grol Richard. Toward a model for field-testing patient decision-support technologies: a qualitative field-testing study. J Med Internet Res. 2007;9(3):e21. doi: 10.2196/jmir.9.3.e21. v9i3e21
    1. Watson Eila, Hewitson Paul, Brett Joanne, Bukach Colleen, Evans Rhodri, Edwards Adrian, Elwyn Glyn, Cargill Anna, Austoker Joan. Informed decision making and prostate specific antigen (PSA) testing for prostate cancer: a randomised controlled trial exploring the impact of a brief patient decision aid on men's knowledge, attitudes and intention to be tested. Patient Educ Couns. 2006 Nov;63(3):367–79. doi: 10.1016/j.pec.2006.05.005.S0738-3991(06)00159-5
    1. Marteau T M, Bekker H. The development of a six-item short-form of the state scale of the Spielberger State-Trait Anxiety Inventory (STAI) Br J Clin Psychol. 1992 Sep;31 ( Pt 3):301–6.
    1. Spielberger CD. State-Trait Inventory for Adults: Sampler Set, Manual, Test, Scoring Key. Palo Alto, CA: Consulting Psychologists Press; 1983.
    1. O'Connor A M. Validation of a decisional conflict scale. Med Decis Making. 1995;15(1):25–30. doi: 10.1177/0272989X9501500105.
    1. O'Connor Annette M, Légaré France, Stacey Dawn. Risk communication in practice: the contribution of decision aids. BMJ. 2003 Sep 27;327(7417):736–40. doi: 10.1136/bmj.327.7417.736. 327/7417/736
    1. Newcombe Robert G. Confidence intervals for an effect size measure based on the Mann-Whitney statistic. Part 1: general issues and tail-area-based methods. Stat Med. 2006 Feb 28;25(4):543–57. doi: 10.1002/sim.2323.
    1. Volk R J, Cass A R, Spann S J. A randomized controlled trial of shared decision making for prostate cancer screening. Arch Fam Med. 1999;8(4):333–40. doi: 10.1001/archfami.8.4.333.
    1. Davison B J, Kirk P, Degner L F, Hassard T H. Information and patient participation in screening for prostate cancer. Patient Educ Couns. 1999 Jul;37(3):255–63. doi: 10.1016/S0738-3991(98)00123-2.
    1. Krist Alex H, Woolf Steven H, Johnson Robert E, Kerns J William. Patient education on prostate cancer screening and involvement in decision making. Ann Fam Med. 2007;5(2):112–9. doi: 10.1370/afm.623. 5/2/112
    1. Schröder Fritz H, Hugosson Jonas, Roobol Monique J, Tammela Teuvo L J, Ciatto Stefano, Nelen Vera, Kwiatkowski Maciej, Lujan Marcos, Lilja Hans, Zappa Marco, Denis Louis J, Recker Franz, Berenguer Antonio, Määttänen Liisa, Bangma Chris H, Aus Gunnar, Villers Arnauld, Rebillard Xavier, van der Kwast Theodorus, Blijenberg Bert G, Moss Sue M, de Koning Harry J, Auvinen Anssi ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26;360(13):1320–8. doi: 10.1056/NEJMoa0810084. NEJMoa0810084
    1. Andriole Gerald L, Crawford E David, Grubb Robert L, Buys Saundra S, Chia David, Church Timothy R, Fouad Mona N, Gelmann Edward P, Kvale Paul A, Reding Douglas J, Weissfeld Joel L, Yokochi Lance A, O'Brien Barbara, Clapp Jonathan D, Rathmell Joshua M, Riley Thomas L, Hayes Richard B, Kramer Barnett S, Izmirlian Grant, Miller Anthony B, Pinsky Paul F, Prorok Philip C, Gohagan John K, Berg Christine D PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26;360(13):1310–9. doi: 10.1056/NEJMoa0810696. NEJMoa0810696

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe